Inclusion Criteria:  Subjects agree to participate in the study and having dated and signed the informed consent form; Subjects who have the capability to communicate, to make themselves understood, and to comply with the study's requirements; Subjects with high-normal blood pressure (SBP= 130-139 mmHg and/or DBP= 85-89 mmHg); Subjects who, according to the SCORE charts, have a low or moderate cardiovascular risk (defined as a total cardiovascular risk < 5%) and for whom, according to 2018 ESC/ESH guidelines, the intervention strategy does not require a pharmacological intervention.  Exclusion Criteria:  Subjects already affected by cardiovascular diseases (secondary prevention) or with an estimated 10 years cardiovascular disease risk> 5%; Obesity (Body mass index>30 kg/m2); Type 1 or type 2 diabetes; Assumption of anti-hypertensive drugs or food supplements, or drugs potentially affecting blood pressure; Lipid-lowering treatment not stabilized since at least 2 months; Anticoagulants therapy; Known current thyroid, gastrointestinal or hepatobiliary diseases; Any medical or surgical condition that would limit the patient adhesion to the study protocol; Abuse of alcohol or drugs (current or previous); History of malignant neoplasia in the 5 years prior to enrolment in the study; History or clinical evidence of inflammatory disease such as severe arthritis, systemic lupus erythematosus or chronic inflammatory diseases or current therapy with immunosuppressive agents or long-term glucocorticoids; History or clinical evidence of any significant concomitant disease that could compromise the safety of the subject or the possibility of completing the study; Known previous intolerance to one component of the tested nutraceuticals; Women in fertile age not using consolidated contraceptive methods; Pregnancy and Breastfeeding.